To Be Discontinued Injection Oncology
Docetaxel Injection · 203 days since initial FDA posting
Brand: DOCETAXEL
FDA lists Docetaxel Injection as To Be Discontinued (Ingenus Pharmaceuticals LLC).
No availability text on this FDA row.
Docetaxel Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Docetaxel Injection
- Manufacturer
- Ingenus Pharmaceuticals LLC
- Dosage Form
- Injection
- Presentation
- Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16)
- Package NDC
- 50742-463-16
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Feb 20, 2026
- Last Updated
- Feb 20, 2026
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
A business decision was made to discontinue manufacture of the drug.
Nearby, Other Docetaxel Shortage Records
FDA reason on file: A business decision was made to discontinue manufacture of the drug. General shortage guidance lives on the tracker hub.